Inclusion Criteria:

          -  Histologically confirmed solid malignancy for which the following treatment regimens
             are warranted:

               -  A. Colorectal Cancer with no prior history of treatment with Irinotecan alone or
                  in combination: FOLFIRI as standard of care

               -  B. Cholangiocarcinoma, Bladder Cancer with no prior history of treatment with
                  Gemcitabine alone or in combination: Gemcitabine / Cisplatin as standard of care

               -  C. Ovarian Cancer who have relapsed at least 6 or more months after completion of
                  a previous platinum-based therapy and have no prior history of treatment with
                  gemcitabine alone or in combination: Gemcitabine / Carboplatin as standard of
                  care

               -  D. Gastric Cancer including Gastroesophageal Junction with no prior history of
                  treatment with Ramucirumab, Paclitaxel or any Taxane class drug: Ramucirumab /
                  Paclitaxel as standard of care

               -  E. Solid Tumors: Eligible for PD1 Inhibitor (Nivolumab or Pembrolizumab)
                  monotherapy as standard of care according to the approved drug label by the
                  relevant regulatory authority

               -  F. Locally advanced or metastatic disease in a cancer with at least one palpable
                  subcutaneous malignant lesion(≤ 2 cm in diameter) for treatment with TRK-950 and
                  Imiquimod cream (US Sites Only)

               -  G. Renal Cell Carcinoma with no prior history of treatment with Bevacizumab alone
                  or in combination: Bevacizumab as standard of care

               -  H. Melanoma patients who progressed while taking Nivolumab, Pembrolizumab, or
                  Ipilimumab, within the last 6 months prior to cycle 1 day 1

               -  I. Melanoma patients who have not been treated with Nivolumab, Pembrolizumab, or
                  Ipilimumab: Nivolumab / Ipilimumab as standard of care

               -  J. Colorectal Cancer patients who progressed on FOLFIRI or any other
                  Irinotecan-containing therapy regimen within the last 6 months prior to cycle 1
                  day 1

          -  Primary or metastatic tumors measurable per RECIST v1.1 on CT scan or by calipers
             (subcutaneous lesions)

          -  Karnofsky performance of ≥70

          -  Life expectancy of at least 3 months

          -  Age ≥ 18 years

          -  Signed, written IRB-approved informed consent

        Exclusion Criteria:

          -  Laboratory values or medications that are contraindicated in the selected standard of
             care treatment regimens

          -  New York Heart Association Class III or IV, cardiac disease, myocardial infarction
             within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG

          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy. Prophylactic antibiotics are acceptable.

          -  Pregnant or nursing women

          -  Treatment with radiation therapy within 2 weeks, or treatment with surgery,
             chemotherapy, immunotherapy, or investigational therapy within four weeks prior to
             study entry.

          -  Unwillingness or inability to comply with procedures required in this protocol

          -  Known active infection with HIV, hepatitis B, hepatitis C

          -  Serious nonmalignant disease that could compromise protocol objectives in the opinion
             of the investigator and/or the sponsor

          -  Patients who are currently receiving any other investigational agent

          -  Any contraindicated condition or drug which would make the patient ineligible for the
             respective treatment regimen that is to be used in combination with TRK-950 (for
             example, autoimmune disorders for nivolumab or pembrolizumab treatment) as described
             in the Full Prescribing Information